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Octreotide is approved as a one-month injectable for treatment of acromegaly and 
neuroendocrine tumours. Oral delivery of the octapeptide is a challenge due mainly to low 
intestinal epithelial permeability. The intestinal permeation enhancer (PE) salcaprozate 
sodium (SNAC) has Generally Regarded As Safe  (GRAS) status and is a component of an 
approved oral peptide formulation. The purpose of the study was to  examine the capacity of 
salcaprozate sodium (SNAC), to increase its permeability across isolated rat intestinal 
mucosae from five regions and across human colonic mucosae mounted in Ussing chambers. 
Apical-side buffers were Kreb’s-Henseleit (KH), fasted simulated intestinal fluid (FaSSIF-
V2), rat simulated intestinal fluid (rSIF), and colonic simulated intestinal fluid (FaSSCoF). 
The  basal apparent permeability coefficient (Papp) of [
3
H]-octreotide was equally low across 
rat intestinal regional mucosae in KH, rSIF, and FaSSIF-V2. Apical addition of 20 mM 
SNAC increased the Papp across rat tissue in KH: colon (by 3.2-fold) > ileum (3.4-fold) > 
upper jejunum (2.3-fold) > duodenum (1.4-fold) > stomach (1.4-fold). 20 mM and 40 mM 
SNAC also increased the Papp by 1.5-fold and 2.1-fold respectively across human colonic 
mucosae in KH. Transepithelial electrical resistance (TEER) values were reduced in the 
presence in SNAC especially in colonic regions. LC-MS/MS analysis of permeated 
unlabelled octreotide across human colonic mucosae in the presence of SNAC indicated that 
[
3
H]-octreotide remained intact. No gross damage was caused to rat or human mucosae by 
SNAC. Attenuation of the effects of SNAC was seen in rat jejunal mucosae incubated with 
FaSSIF-V2 and rSIF, and also to some extent in human colonic mucosae using FaSSCoF, 
suggesting interaction between SNAC with buffer components. In conclusion, SNAC showed 
potential as an intestinal permeation enhancer for octreotide, but in vivo efficacy may be 
attenuated by interactions with GI luminal fluid contents. 
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1. Introduction 
Acromegaly is a hormonal disorder that occurs due to the presence of a pituitary adenoma, 
resulting in chronic overproduction of growth hormone. It is an orphan disease with an 
annual prevalence of 30-60 cases/million people (Capatina and Wass, 2015). Treatment 
includes surgery and therapeutic strategies to improve co-morbidities and quality of life (Lim 
and Fleseriu, 2017). Peptides are highly potent and selective, and generate lower toxicity 
compared to small molecules, making them attractive candidates for disease treatment (Lau 
and Dunn, 2018). FDA-approved somatostatin peptide analogues for acromegaly include 
octreotide and lanreotide. The octapeptide, octreotide (molecular weight (MW) 1019 Da) is a 
first-generation synthetic analogue with a longer circulating t½ than native somatostatin 
(Pless, 2005; Yang and Keating, 2010). Injectable formulations of octreotide have been 





LAR depot (Novartis, Geneva, Switzerland) (Fattah and Brayden, 2017). According to a 
recent extensive survey however, a majority of patients with acromegaly stated that “an oral 
therapy and/or a treatment to avoid injection” would be preferable to current injectable 
analogues (Strasburger et al., 2016), whose administration is especially pain-inducing due to 
use of low gauge needles. A once-daily oral formulation of octreotide would therefore be 
attractive to patients and would improve compliance. The main challenges to address for oral 
delivery of peptides, however, relates to their metabolic instability in the gastrointestinal (GI) 
tract and very low permeability across intestinal epithelia (Brayden et al., 2020; Brown et al., 
2020; Drucker, 2020). 
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Octreotide is cyclic and contains D-amino acids and a disulphide bridge, which confer some 
stability against intestinal peptidases compared to typical linear peptide candidates (Wang et 
al., 2015). Nonetheless, the hydrophilicity and high MW of octreotide result in low intestinal 
epithelial permeability and this is the main reason for its low oral bioavailability. Some 
delivery technologies have improved oral octreotide delivery in preclinical and clinical 
studies (Fattah and Brayden, 2017). An oral octreotide formulation (Mycappsa®, Chiasma 
Pharma, Jesusalem, Israel) uses Transient Permeability Enhancer™ (TPE™), developed by 
Chiasma Pharma (Jerusalem, Israel), recently received the approval of the US FDA for an 
octreotide capsule using Transient Permeation Enhancement™ technology for oral use in 
acromegaly patients (Melmed et al., 2015; “MYCAPSSA,” 2020).  
This technology involves formulating octreotide in an oily suspension with intestinal 
permeation enhancers (PE). Briefly, the capsule consists of the medium chain fatty acid PE, 
sodium caprylate (C8) and other excipients, combined with octreotide in an oily suspension, 
which is then encapsulated in a pH-dependent polymeric enteric coating (Ben-Shlomo et al., 
2017). In rat intestinal instillation studies, C8 and the other excipients in TPE™ induced a 
transient opening of small intestinal tight junctions, a likely basis for enhancing the 
paracellular permeability of octreotide (Tuvia et al., 2014). Examination of the 
pharmacokinetics of octreotide in the TPE™ formulation from a Phase I study indicated that 
the oral bioavailability of Mycappsa™ was only ~0.25% (Tuvia et al., 2014). Co-formulation 
of octreotide with other PEs has been investigated to some extent, but none of these studies e 
progressed to clinical trials (Fricker et al., 1996; Fricker and Drewe, 1995; van der Merwe et 
al., 2004). Overall, This would suggest that there is an opportunity to further increase the oral 
bioavailability of octreotide using alternative formulations with more efficacious PEs than 
C8. 
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The 2019 FDA-approval of oral semaglutide (Rybelsus
®
, Novo Nordisk, Copenhagen, 
Denmark) is likely to increase interest in oral formulations of other suitable peptide 
candidates (Bucheit et al., 2019). Rybelsus
®
 was the first glucagon-like peptide-1 (GLP-1) 
receptor agonist to be approved by FDA for Type 2 diabetics by the oral route and it is 
administered once-a-day. Even though its oral bioavailability in humans is 0.4 – 1.0% 
(“RYBELSUS®,” 2020), this is still higher than Mycappsa®The  non-enteric coated tablet 
consists of either 7m or 14 mg semaglutide with the PE, 300 mg of salcaprozate sodium 
(SNAC). SNAC prevents semaglutide degradation by pepsin through modifying the pH 
around the tablet and by promoting permeability of monomeric semaglutide across the 
stomach mucosa (Buckley et al., 2018). SNAC was  discovered as a lead PE in the Eligen
®
 
technology by Emisphere (Roseland, NJ, USA), whose researchers hypothesized that it could 
chaperone poorly-permeable macromolecules across plasma membranes via a transcellular 
mode of action (Park et al., 2011). Over the past 20 years, several other  mechanisms of 
action of SNAC were proposed on the basis that is it  surfactant-like and is structurally 
related to salicylic acid and medium chain fatty acids (Maher et al., 2019; Twarog et al., 
2019). From a regulatory standpoint, SNAC has generally regarded as safe status (GRAS) 
and has also been marketed as an oral vitamin B12 supplement (Eligen
®
-vitamin B12, 
Emisphere, USA) under Medical Food rules for several years (Castelli et al., 2011).  
The main aim of this study was therefore to examine the potential of SNAC to promote 
intestinal permeability of octreotide across rat and human tissue ex vivo. We investigated the 
effects of SNAC on the apparent permeability coefficient (Papp) of [
3
H]-octreotide across 
isolated rat intestinal tissue mucosae from five regions and from colonic human mucosae 
mounted in Ussing chambers. A second aim was to develop a liquid chromatography-mass 
spectrometry (LC-MS/MS) method for octreotide detection to provide evidence that there 
was no radiolabel degradation during ex vivo fluxes of [
3
H]-octreotide. The third aim was to 
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assess the Papp of [
3
H]-octreotide in biorelevant simulated buffers bathing the apical sides of 
isolated rat and human tissue mucosae in order to determine if potential components of 
luminal fluids could interfere with SNAC performance. The results show that SNAC acts as a 
PE for the peptide with increasing efficacy in rat intestinal mucosae in the proximal-distal 
region direction as well as in human colonic mucosae in physiological Krebs-Henseleit (KH) 
buffer. However, efficacy was attenuated in biorelevant buffers, suggesting that SNAC 
performance in vivo may be over-predicted from standard Ussing chamber studies in KH 
buffer.  
2. Materials and Methods 
2.1. Materials  
Octreotide (> 95% purity) was purchased from ChinaPeptides Co., Ltd (Shanghai, China). 
[
3
H]-octreotide (specific activity, 0.7 Ci/mmol) was obtained from Moravek, Inc. (Brea, CA, 
USA). Ecoscint A, liquid scintillation cocktail, was from National Diagnostics (Atlanta, GA, 
USA). Salcaprozate sodium (SNAC, MW 301 Da, > 99% purity) was obtained from 
Shanghai Boc Chemicals Co., Ltd (Shanghai, China). Fasted State Simulated Intestinal Fluid-
V2 (FaSSIF-V2) and Fasted State Simulated Colonic Fluid (FaSSCoF) were purchased from 
Biorelevant.com Ltd (London, UK). All other reagents and chemicals were purchased from 
Sigma-Aldrich (Arklow, Ireland).  
2.2. Methods 
2.2.1. Media  
Composition of buffers are shown in Table 1. KH buffer was prepared in deionized H2O at 
pH 7.4 with carbogen bubbling. Rat simulated intestinal fluid (rSIF) was prepared as 
prescribed (Berghausen et al., 2016). It was prepared by dissolving sodium taurocholate, 
sodium cholate hydrate, sodium chenodeoxycholic acid, and NaCl in 50 ml deionized H2O 
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and stirred for approximately 30 min at room temperature. Lecithin, sodium oleate, and 
glyceryl monooleate were added and the mixture was sonicated for 10 min and left stirred 
overnight to yield a clear solution. Malenic acid and 40 ml deionized H2O were added and the 
pH was adjusted to 6.0 with 1N NaOH. It was stirred until a clear solution was obtained and 
finally the buffer volume was made up to 100 ml with deionized H2O. FaSSIF-V2 (pH 6.5) 
and FaSSCoF (pH 7.8) were made up according to the manufacturer’s protocol (Biorelevant 
Ltd). The buffers were used within 48 h of preparation and were stored at room temperature. 
2.2.2. Preparation of dissected rat intestinal tissue for Ussing chamber studies 
Male Wistar rats (250-300 g, from Charles River Staffron Walden, UK and the UCD 
Biomedical Facility, Ireland) were used to study permeability. Rats were housed and used 
according to the National Institute of Health directive: “Principle of Laboratory Animal Care” 
(NIH publication number 85-23, 1985). Approval of this project was granted by the UCD 
Research Ethics Committee for animal experimentation (AREC approval number 14-28-
Brayden). Rats were euthanized by stunning and cervical dislocation. After laparotomy, 
resected duodenum (up to 10 cm from pylorus), upper jejunum (< 11 cm from pylorus), ileum 
(up to 10 cm above the caecum) and colon were placed in carbogenated KH buffer and 
dissected according to previous descriptions (Cuthbert and Margolius, 1982). Muscle-
stripped stomach mucosae was prepared by a blistering technique (Hopkins et al., 2002). 
Dissected tissues were mounted between two halves of chambers and maintained in 5 ml 
temperature-controlled carbogenated KH buffer on each side and with an exposed window 
area of 0.63 cm
2
. Baseline potential difference (PD, mV) and short circuit current (Isc, 
µA.cm
-2
) were measured using a DVC 4000 Voltage Clamp (WPI, Hichin, UK) by using a 
PRO-4 timer (WPI) to switch between open circuit- and voltage clamping to zero, 
respectively. Transepithelial electrical resistance, TEER (Ω.cm
2
) was calculated by Ohm’s 
Law (Equation 1).  
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                            ⁄  
Tissues from stomach, duodenum, jejunum, and ileum with minimum TEER values > 30 
Ω.cm
2
 and colonic mucosae with minimum TEER values > 70 Ω.cm
2
 were used for 
permeability studies (Petersen et al., 2012; Ungell et al., 1998). Analogue data was digitised 
with a Powerlab® data acquisition unit and analyzed with Chart® software package (AD 
Instruments, UK). 
2.2.3. Preparation of dissected human colonic mucosae for Ussing chamber studies  
Human colonic specimens were sourced from surgical colon resections. Ethical approval for 
this study (Protocol 190/2012) was obtained from the St. Vincent's University Hospital 
Institutional Review Board, and it included informed patient consent. Resections were 
obtained from patients with suspected colorectal carcinoma. After resection, fresh normal 
human colonic tissue specimens were obtained from above the diseased margin as designated 
by a pathologist. Specimens were incubated in ice-cold phosphate buffered saline (PBS). 
When the tissue arrived at laboratory within 60 min of excision, it was transferred into fresh 
carbogenated ice-cold KH buffer and kept on ice. Subsequently, the tissue was transferred to 
a dissection bowl containing carbogenated ice-cold KH buffer (Figure 1). The tissue was 
pinned with the luminal side down on a dissection board. The circular and longitudinal 
smooth muscle of human colonic tissue was dissected from the basolateral side of mucosae 
(Kisser et al., 2017) using size 5 watchmaker forceps. Stripped mucosae were mounted in 
pre-equilibrated Ussing chambers (WPI) as described above within 2-3 h of resection. 
Mucosae with minimum TEER values > 70 Ω.cm
2
 were used for permeability studies (Maher 
et al., 2009).  
2.2.4. Fluxes of octreotide across isolated rat and human intestinal mucosae  
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The apparent permeability (Papp) values of either [
3
H]-octreotide (0.5μCi/ml) or unlabelled 
octreotide (10μM) were assessed across intestinal tissues from rat and human in the presence 
of SNAC. [
3
H]-octreotide and octreotide with or without SNAC (20 mM and 40 mM) were 
added to the apical compartment bathing mucosae and 0.2 ml samples were taken from 
basolateral compartment every 20 min over 120 min. Each basolateral sample was replaced 
an equal volume of KH buffer. Some studies were also carried out in the presence of 
biorelevant media, rSIF, FaSSIF-V2, and FaSSCoF, which were added to apical compartment 
only, with KH retained on the basolateral side otherwise. These investigations were carried 
out in order to better model in vivo GI conditions that may affect drug and PE solubility and 
permeability. Human FaSSIF-V2 is now being widely used by researchers to incubate 
isolated rat intestinal mucosae in order to determine permeability and solubility in biorelevant 
buffers (Berghausen et al., 2016; Forner et al., 2017; Wuyts et al., 2015). Given that the bile 
salt concentrations are 3 mM in FaSSIF-V2 and 25 mM in rSIF, differences in in vitro 
permeability of octreotide might be expected as bile salts are also  recognised as efficacious 
PEs (Berghausen et al., 2016; Brown et al., 2020). Therefore, we used both rSIF (to mimic rat 
luminal contents in vivo), as well as FaSSIF-V2 (to model those of the human small 
intestine). Previous studies demonstrated compatibility between rat isolated small intestinal 
tissue mucosae using FaSSIF-V2 in the apical compartment of Ussing chambers (Forner et 
al., 2017; Wuyts et al., 2015). Fed-state simulated intestinal fluid (FeSSIF) was not used as it 
is too damaging to isolated rat jejunal mucosa (Kristin et al., 2017) and could give rise to 
false-positive flux data.  
The fluxed samples of [
3
H]-octreotide were mixed with 3 ml liquid scintillation cocktail 
(Ecoscint A), and radioactivity was quantified using a liquid scintillation counter (Packard 
Tricab 2900 TR, PerkinElmer, Massachusetts, USA).  
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Unlabelled octreotide samples were quantified using LC-MS/MS. These samples were mixed 
with chilled MS grade acetonitrile and stored at -20°C until analysis. Thawed samples were 
centrifuged at 15,000 rpm at 4°C and analysed. The LC-MS/MS system consisted of a triple 
quadrupole mass spectrometer coupled to a UHPLC system (6470 Triple Quad LC/MS 
(Model G6470A) Agilent Technologies, California, USA). An AdvanceBio Peptide Map 
column (2.7 µm, 150 x 2.1 mm) (Agilent Technologies) was used. The injection volume was 
2 µl. The chromatographic conditions were: 400 µl/min flow rate for 10 min, with the mobile 
phase consisting of (A) 0.1% formic acid and (B) acetonitrile. The gradient A:B (v/v) was 
programmed as follows: from 0 to 4 min the ratio of A:B 90:10 to 20:80 which was 
maintained for 1 min. The column was re-equilibrated for the next 5 min with the initial ratio 
of mobile phase. The transition from m/z 510.3 to m/z 120.1 was used to quantify octreotide, 
with analysis was done using a multiple reaction monitoring (MRM) model. MRM 
parameters are from Ismaiel et al., (Ismaiel et al., 2011) with slight modification: Dwell time 
200 ms, collision energy 48, Cell Accelerator Voltage 5 and Fragmentor 5. The Papp values of 
[
3
H]-octreotide and octreotide were calculated according to the following Equation 2:  
                                ⁄           ⁄  
where dQ/dt was the transport rate across the epithelium (mol/s), A was the surface area of 
the cell monolayer (0.63 cm
2
), and C0 was the initial concentration of [
3
H]-octreotide or 
octreotide in the apical donor compartment (mol.ml
-1
) (Kisser et al., 2017).  
2.2.5. Histology of tissue mucosae 
Following the 2 h permeability experiments, rat and human tissues were removed from the 
chambers and fixed in 10% w/v buffered formalin for histology to evaluate potential 
epithelial damage. After 24 h, the tissues were embedded in paraffin wax. Tissue sections of 
5 µm thickness were cut with a microtome (Leitz 1512; GMI, Minnesota, USA) and stained 
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with haemotoxylin/eosin (H & E) and examined with a light microscope (BX43, Olympus, 
Tokyo, Japan). 
2.3. Statistical analysis 
Statistical analysis was carried out using Prism-8
® 
software (GraphPad, San Diego, USA). 
Results are given as mean ± standard error of mean (SEM). Student’s t-tests (unpaired) and 
ANOVA were used for group comparisons with post hoc tests used for the latter. Statistical 
significance was considered present if p < 0.05.  
3. Results 
3.1. SNAC increases the Papp of [
3
H]-octreotide across rat intestinal mucosae in KH 
The effects of 20 mM SNAC in KH buffer were examined on the Papp of [
3
H]-octreotide 
across rat intestinal mucosae isolated from five regions: stomach, duodenum, upper jejunum, 
ileum, and colon. The basal Papp of [
3









across mucosae from each region, but they were not different from each other (Figure 
2A). The SNAC concentration was below its critical micellar concentration of 36 mM in KH 
buffer (Suppl. Figure 1). In stomach mucosae, apical addition of SNAC increased the Papp to a 








. In the presence of SNAC, the Papp 









, but neither trend was significant. Statistical increases in the 


























, respectively (Figure 2A). There was 
therefore a pattern indicating increasing efficacy of 20 mM SNAC in KH buffer in the order 
of stomach < duodenum < jejunum < ileum < colon (Figure 2A). These results indicate 
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regional effects of SNAC as a PE for this peptide in rat intestinal tissue with increasing 
efficacy observed in the proximal-to-distal direction.  
TEER values in the presence of [
3
H]-octreotide gradually declined to ~40% of the initial 
TEER over 120 min in tissues from the different GI regions from rats (Figure 2B-F). These 
changes in TEER were similar to patterns observed in untreated rat intestinal mucosae 
(Stuettgen and Brayden, 2020; Twarog, 2020), so there was no indication that [
3
H]-octreotide 
itself might be causing TEER reductions across mucosae from the five regions. Following 
apical addition of 20 mM SNAC however, TEER values were further reduced across four of 
the regions compared to [
3
H]-octreotide-exposed controls, except for duodenal mucosae. The 
times required for significant reductions in TEER when exposed to SNAC compared to the 
respective tissue controls ([
3
H]-octreotide alone) were: stomach from 20 - 120 min (20% - 
40% reduction), jejunum at 120 min (35% reduction), ileum from 80 - 120 min (30% - 38% 
reduction), and colon from 15 -120 min (44% - 83% reduction) (Figure 2B-F).  
3.2. No effects of SNAC on the Papp of [
3
H]-octreotide across rat jejunal mucosae in 
rSIF or FaSSIF-V2 
We further investigated the permeability of [
3
H]-octreotide across rat intestinal tissue 
mucosae by replacing KH buffer on the apical side with simulated intestinal fluids as 
indicated in section 2.2.4.  
Since 20 mM SNAC induced a significant increase in the Papp of [
3
H]-octreotide across rat 
upper jejunal mucosae in KH buffer, we re-examined whether this effect pertained in tissues 
just from this region in the presence of rSIF and FaSSIF-V2 on the apical side. The basal Papp 
for [
3














However, attenuation of the permeation-enhancement effects of SNAC in KH buffer was 
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observed in both rSIF and FaSSIF-V2. The Papp of [
3
H]-octreotide in the presence of 20 mM 








, respectively, not 
different from the control Papp in these buffers. Yet these values were both lower than the Papp 




) (p < 0.05) (Figure 3A). 
Since the critical micellar concentration (CMC) of SNAC in rSIF and FaSSIF-V2 was 
lowered to 5.6 mM and 6.3 mM, respectively, an explanation is that the free concentration 
was of SNAC was reduced in these buffers due to mixed micelles forming in the presence of 
NaTC and lecithin contributions (Suppl. Figure 1). 
There was a trend of a slight gradual reduction in TEER values over 2 h in control tissues 
exposed to [
3
H]-octreotide in rSIF and FaSSIF-V2 buffers. In turn, these reductions were 
similar to the gradual pattern for TEER reduction seen in KH buffer, indicating compatibility 
of jejunal tissue with these biorelevant media over this period (Figure 3B). This result 
indicated compatibility of these two simulated small intestinal buffers with isolated intestinal 
tissue mounted in Ussing chambers (Forner et al., 2017; Jantratid et al., 2008; Wuyts et al., 
2015). 20 mM SNAC did not cause additional TEER reductions in jejunal tissue in either 
simulated buffers, in contrast to additional reductions observed in the presence of SNAC in 
KH.  
3.3. SNAC increases the Papp of octreotide across human colonic mucosae in KH buffer 
Due to difficulty in accessing sufficient human specimens from different GI regions, we were 
limited to investigating effects of SNAC on the Papp of [
3
H]-octreotide in human colonic 
mucosae, where surgeries to obtain tissue are common. Following apical addition of SNAC 














 (Figure 4A) for [
3
H]-octreotide alone. Therefore, 40 mM SNAC was required to 
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statistically achieve same effect in human colonic mucosae as seen for the rat counterpart (20 
mM).  
We developed an LC-MS/MS method to quantify unlabelled octreotide on the basolateral 
side in order to confirm the data seen with [
3
H]-octreotide in KH buffer and to show that 
measurement of the radiolabel did not reflect metabolism of the link between tritium and 
octreotide during transit. Following addition of 40 mM SNAC, the Papp of unlabelled 









although this trend was not quite significant (p= 0.23) (Figure 4C). The Papp values for 
labelled and unlabelled octreotide were therefore of the same order, indicating that both sets 
of values were a true measure of intact peptide flux. Had tritium split from octreotide, the Papp 




 (Twarog, 2020). 
The effect of SNAC on the TEER of human colonic mucosae was investigated. The mean 
basal TEER was 99.6 ± 9.5 Ω.cm
2
 (n=24), similar to values reported by others (Maher et al., 
2009; Petersen et al., 2012). Following 120 min incubation, the mean TEER of control tissues 
exposed to [
3
H]-octreotide gradually decreased by a small amount, ~25% (Figure 4B),  
similar to control tissues in the absence of [
3
H]-octreotide, so there was no indication that 
[
3
H]-octreotide reduced TEER in human colonic mucosae per se. Upon apical addition of 
either 20 mM or 40 mM SNAC, there was additional reduction in TEER compared to 
controls (Figure 4B and C). 
3.4. Attenuated effects of SNAC on the Papp of octreotide across human colonic 
mucosae in FaSSCoF 
In an attempt to better mimic the in vivo situation where the luminal side of intestinal fluid is 
exposed to bile salts and lecithin, we used a simulated human colonic buffer on the apical 
side of human colonic tissue. FaSSIF-V2 is considered suitable for the upper small intestinal 
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region (Forner et al., 2017; Jantratid et al., 2008), so we tested the effects of SNAC on the 
Papp of [
3
H]-octreotide using a human colonic version, FaSSCoF. The Papp of [
3
H]-octreotide 













 in the presence of 20 mM and 40 mM SNAC, respectively, but 
statistical significance was not reached (Figure 5A). TEER values of control tissues exposed 
to [
3
H]-octreotide in FaSSCoF were unchanged over 2 h, whereas in the presence of SNAC 
(20 mM, 40 mM), TEER values decreased further (Figure 5B).  
3.5. Minor changes in intestinal mucosae morphology in the presence of SNAC in KH 
Histology of rat and human tissue mucosae following exposure to SNAC over 120 min was 
assessed (Figure 6A and B). Rat stomach mucosae exposed to KH buffer and 20 mM SNAC 
were structurally intact with just minor perturbation observed (Figure 6A). In rat duodenal 
and jejunal mucosae, minor cell sloughing at the tip of villi was seen in control and SNAC-
exposed tissues. More sloughing was noticeable in rat ileal and colonic mucosae where the 
tips of villi were absent following exposure to SNAC (Figure 6A). As seen in Figure 6B, 
human colonic mucosae in KH buffer appeared structurally intact with healthy villi present, 
similar to that of control tissue. Human tissues exposed to 20 mM SNAC showed minor 
damage to villi tips, whereas 40 mM SNAC caused tip erosion.  
Discussion 
PEs have potential to increase the bioavailability of poorly permeable drugs and 
macromolecules (Maher et al., 2019, 2016). The approval of Rybelsus
®
 (oral semaglutide) for 
the treatment of Type 2 diabetes is rightly considered a landmark for oral peptide delivery 
and offers encouragement to use PE-containing formulations to be used for other peptides 
even though the oral bioavailability is ~1% (“Rybelsus® (oral semaglutide),” 2020). Upon 
closer scrutiny however, rather than opening up the oral peptide field for use with PE 
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formulations, it restricts it to niche peptides as only highly potent peptides of reasonable MW, 
with acceptable stability, a long t½, and a large therapeutic index can be considered as 
candidates at that low and variable level of bioavailability. Perhaps such candidates will 
emerge through the efforts of medicinal chemistry, which is focussed on producing 
membrane-permeable stable macrocycles of lower MW than typical linear peptides (Naylor 
et al., 2017). For this study, we selected octreotide because it displays several of those 
promising features, although its stability in the GI tract is still relatively low despite its cyclic 
structure (Wang et al., 2015). Moreover, an oily suspension largely based on the PE, C8, was 
recently approved by the FDA despite an oral bioavailability of ~0.25%, so there is potential 
to further improve its systemic delivery. We paired octreotide with SNAC as a well-
established PE, present in Rybelsus® at a daily level of 300 mg per dose. It is not necessarily 
the most efficacious PE (that is typically pay-load dependent), but it has an excellent safety 
record, GRAS status, and can be produced to Good Manufacturing Practice (GMP) quality in 
large quantities. SNAC is  already on the market as a component of an oral semaglutide 
formulation (Rybelsus®) since 2019.. 
Here, we demonstrated that SNAC is efficacious at increasing octreotide flux across isolated 
rat and human intestinal mucosae in the standard KH physiological buffer used for ion 
transport and drug flux studies across epithelial mucosae mounted in Ussing chambers. This 
was not a particular surprise as SNAC is well-known to have capacity to increase oral 
absorption of several co-administered poorly permeable molecules apart from semaglutide 
including unfractionated heparin, cromolyn, and vitamin B12 (Leone-Bay et al., 1998, 1996; 
Smith et al., 2016). Yet, exact mechanism of action remains controversial, recently it has 
been provided a specific mechanism for SNAC in respect of close association with 
semaglutide in a tablet in the stomach, based on buffering against acid, protection against 
pepsin, and presentation of semaglutide to the gastric epithelium as a monomer (Buckley et 
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al., 2018). In that study, it was suggested that neither replacing semaglutide with another 
GLP-1 analogue, liraglutide, nor replacing SNAC with another Eligen™ PE analogue 
sufficed to increase flux across gastric epithelial monolayers. The gastric mechanism of 
action of SNAC in respect of semaglutide that was demonstrated in ligated dogs does not, 
however, rule out SNAC effects in other GI regions with other payloads where it can exert 
membrane perturbation due to its surfactant structure and capacity to alter a range of 
epithelial intracellular parameters (Twarog, 2020).  
The basal Papp was low and equivalent for [
3
H]-octreotide across all five regions, as expected 
for a hydrophilic peptide of MW ~1000 Da. Similarly, Forner et al., also showed that the Papp 
of FITC-labelled dextran 4000 (FD4) was constant across different rat intestinal regional 
mucosae (Forner et al., 2017). Peterson et al., on the other hand demonstrated regional 
differences in the basal Papp of [
14
C]-mannitol and FD4, with higher permeability observed in 
isolated rat jejunal- than colonic mucosae (Petersen et al., 2012). In the current study and that 
of Forner et al., the upper jejunal region was used while in Petersen et al., the distal jejunum 
was used instead. These two jejunal regions may have different basal permeabilities. In 
addition, while mannitol and FD4 fluxes are mediated by the paracellular pathway, octreotide 
flux can be mediated by both transcellular and paracellular pathways (Fricker et al., 1992, 
1991), another possible source of variation. 
SNAC’s effects were regional-dependent in rat tissue in KH buffer, with greater efficacy as a 
PE at increasing the Papp of [
3
H]-octreotide in the proximal-to-distal direction. To our 
knowledge, this is the first study to systematically evaluate regional differences of SNAC as a 
PE for octreotide across rat intestinal mucosae. A recent presentation from Merck (NJ, USA) 
also investigated the capacity of SNAC to increase flux of octreotide across isolated rat 
intestinal mucosae mounted in diffusion chambers (“Novel Approaches for Enhancing the 
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Oral Bioavailability & Absorption of Peptides,” 2020). Flux was increased by 4.8% w/v 
SNAC, equivalent to 66 mM, more than a 3-fold higher concentration than used here. No 
histology was presented in the Merck study and the intestinal region was not stated. 
Nonetheless, it corroborates some of the findings of this project. In the current study, 
SNAC’s efficacy as a PE was weakest in stomach mucosae for this payload. In Buckley et 
al., rat gastric mucosae were mounted in chambers and exposed to 10-30 mM SNAC. Their 
results showed an increase in permeability of semaglutide during an acute 10 min exposure to 
SNAC followed by removal of the PE-containing buffer, with efficacy gradually declining at 
30 and 60 min (Buckley et al., 2018). In our study, the gastric mucosa was exposed 
chronically to 20 mM SNAC over 2 h, so constant exposure to SNAC in this design would 
favour a sustained effect on the epithelium, even if acute exposure is a more likely scenario in 
vivo (Buckley et al., 2018). Irrespective, there is no doubt that the efficacy of SNAC as a PE 
on rat stomach mucosae is markedly different between these studies: this could be down to 
differences in stomach dissection technique, or that SNAC is simply more efficacious with 
semaglutide than with octreotide in stomach mucosa. Taken together, since the stomach 
appears less amenable to PEs than regions lower down the GI tract, the gastric mode of action 
for SNAC in the oral formulation of semaglutide is likely to be built primarily upon pH-
buffering and monomer induction rather than relying on stomach permeation-enhancement. 
Small intestinal regional absorption has in fact been demonstrated before for octreotide. 
Fricker et al., showed higher uptake of octreotide from jejunum than ileum from humans and 
rats (Fricker et al., 1992, 1991). Despite efficacy observed for SNAC in respect of the Papp of 
[
3
H]-octreotide in rat distal intestinal mucosae in the current study, it still took a 
concentration of 20 mM to achieve it, reflecting its low potency. This is consistent with a 
requirement for 300 mg in the oral semaglutide tablet, a weight ratio of 21:1 (SNAC : 
peptide).  
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Targeting and releasing drug contents in the colonic region has been advocated for 
formulations that act locally (Bak et al., 2018). Compared to the small intestine, the colon has 
a lower surface area compensated by a longer transit time (20-30 h), which permits a longer 
time to release the material (Jones et al., 2016). The observation of increased efficacy of 
SNAC in lower GI intestinal mucosae is in line with other studies of PEs with isolated rat 
intestinal mucosae (Maroni et al., 2012; Petersen et al., 2012; Yamamoto et al., 1997). The 
PE, sodium caprate (C10), also demonstrated superior efficacy in isolated rat colonic mucosae 
compared to jejunal in respect of promoting flux of macromolecule (Maroni et al., 2012; 
Petersen et al., 2012; Yamamoto et al., 1997). Recently, our group also showed efficacy of 
another PE class, piperazine derivatives, on increasing the Papp of [
3
H]-octreotide across rat 
colonic mucosae (Stuettgen and Brayden, 2020). It is not known why the colon seems to be 
especially amenable to many PEs, but it is possible that the plasma membrane lipid 
composition of colonic enterocytes may be different from the small intestine. A more likely 
explanation is that the small intestine has adapted to coping with up to 20 mM bile salts in the 
fed state along with challenges from nutrients, so that it should be more resilient seems 
intuitive. Even if the colon is arguably the most amenable site for PE to act, it is still not a 
very attractive option for the systemic delivery of peptides due to the variable GI transit time 
to reach there with coated oral dosage forms and also due to the complexity of the colon-
microbiome interaction (Bak et al., 2018). The histological observations of just mild 
perturbation observed with SNAC in mucosae from different GI regions from rats are in line 
with effects of other surfactant-type PEs (Maher et al., 2018; McCartney et al., 2019; 
Stuettgen and Brayden, 2020). 
The basal Papp values of [
3
H]-octreotide across rat jejunal and human colonic mucosae were 
not altered in the biorelevant buffers compared to KH buffer. Forner et al., also observed 
similar Papp values for FD4 and atenolol in HBSS versus modified FaSSIF on the apical side 
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of isolated rat jejunal mucosae (Forner et al., 2017). Attenuation of the efficacy of SNAC was 
however seen here in FaSSIF-V2 and rSIF, and to lesser extent with FaSSCoF. The lack of 
effect of SNAC on the Papp of [
3
H]-octreotide seen in these buffers is likely to be due to 
interaction of SNAC with components of simulated fluids since basal fluxes were unchanged. 
Several factors might contribute to the attenuation of SNAC’s effects in the simulated fluids. 
The initial study showing efficacy of SNAC was carried out in rat and human intestinal tissue 
in KH buffer at pH 7.4, whereas both FaSSIF-V2 and rSIF were used at pH < 6.5. Even with 
even a small change in pH, different dissolution profiles can be obtained (Berben et al., 2019; 
Falavigna et al., 2019). A difference in pH might affect the solubility of SNAC (Cumming 
and Martin, 2000). SNAC is the sodium salt of a weak acid with a pKa of 5.01. At low pH, 
the solubility of SNAC decreases and the SNAC precipitates as the SNAC free acid form 
(Cumming and Martin, 2000). Changes in pH could also alter the degree of ionization of 
octreotide, but this does not seem relevant, otherwise a decrease in the basal Papp would have 
been detected. It is also possible that a change in pH could affect the interaction between 
SNAC and octreotide. A decrease in pH can also alter rheology of mucus, which might 
increase the barrier for the peptide or PE to reach the epithelium (Berben et al., 2019; 
Falavigna et al., 2019). 
SNAC might also be entrapped in micelles by key components of biorelevant fluids, bile salts 
and lecithin, thereby reducing its free concentration. Both sodium taurocholate (NaTC) and 
lecithin form colloidal structures in simulated intestinal fluids, while FaSSIF consists of 
mixed-micelles of different sizes (40-100 nm). Gradauer and colleagues also saw similar 
attenuation in efficacy of the non-ionic surfactant PE, tetradecyl maltoside (Gradauer et al., 
2015). In that study, the enhancement capacity of the maltoside to increase permeability of 
FD4 was reduced in FaSSIF-V2 across Caco-2 monolayers and in rat intestinal instillations. 
The authors provided evidence for entrapment of the maltoside at concentrations above its 
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CMC in mixed micelles comprising NaTC/lecithin. Whether this occurs for SNAC is unclear 
as its CMC in KH buffer is 36 mM, above the 20 mM concentration that proved efficacious 
in rat tissue, but lower than the 40 mM concentration required for human colonic mucosae. 
However, the CMC of SNAC in rSIF and FaSSIF was 5.6 mM and 6.3 mM, respectively, so 
it is likely that mixed micelles form in these buffers that lead to reduction in its free 
concentration, thereby providing a plausible explanation for the lack of effect. 
Evaluation of permeability and PE effects using simulated colonic fluid with human mucosa 
on Ussing chambers has to our knowledge never been conducted before. To date, only 
dissolution of molecules has been determined in this new buffer, so it needs verification to 
confirm its suitability for predicting permeability in human colonic mucosae (Augustijns et 
al., 2014; Vertzoni et al., 2019, 2010). However, incubating human colonic mucosae in KH 
buffer is well-established and yields correlation with fraction absorbed across human colon in 
vivo (Lennernäs, 2007). The Ussing chamber was originally designed for epithelial 
electrophysiology, with TEER measurement used to monitor electrical leakiness of tight 
junctions, as well as the integrity of the mounted tissues. Reduction in TEER is not an 
indication of toxicity or paracellular mode of action, as transcellular perturbation can also 
reduce TEER (Maher et al., 2019). Hess et al., demonstrated that SNAC (33-66 mM) could 
increase the permeability of polar marker molecule, 6-carboxy-fluorescein in isolated rat 
jejunal mucosae, surprisingly without reducing TEER values at such high concentrations 
(Hess et al., 2005). Thus, the reduction in TEER induced by SNAC in the mucosae of the 
current study reveals very little on electrophysiology changes, permeability pathways, or the 
mechanism of action. It is more likely to simply reflect the mild perturbation seen in the 
histology images.  
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In conclusion, the effect of SNAC as a PE for octreotide permeability across in human and rat 
intestinal membrane was evaluated. Regional differences were found for the SNAC 
enhancement effect with the best efficacy seen in rat colon, which was confirmed for human 
colon. Moreover, the influence of rSIF and FaSSIF-V2 on the permeability of octreotide in 
presence of SNAC was investigated which resulted in attenuation of the PE effect, likely 
related to entrapment in micellar components of simulated fluid containing NaTC and 
lecithin, leading to a reduction in the free concentration that can access the plasma 
membrane. Finally, our results showed compatibility of simulated fluids mapped to intestinal 
regional mucosae in Ussing chambers. Use of biorelevant compatible buffers for ex vivo 
fluxes which mimic the lumen contents of intestinal regions have the potential to offer more 
complex mechanistic insights for how PEs act and more accurate predictions of in vivo 
outcomes. Whether SNAC can be formulated in tablets with octreotide to compete with the 
very low oral bioavailability in humans offered by TPE™ will require initial assessment in 
large animal studies.   
         
23 
 
Authorship contribution statement 
Sarinj Fattah: conceptualization, data curation, formal analysis, investigation, writing draft, 
methodology and funding acquisition.  




and Jesus M. Frias: analytical methodology for octreotide and data 
analysis 
David J. Brayden: conceptualization, supervision, writing and review of drafts, investigation, 
and funding acquisition. 
Acknowledgment: Sarinj Fattah received funding from the European Union’s Horizon 2020 
research and innovation programme under the Marie Skłodowska-Curie Grant agreement No 
666010 and Science Foundation Ireland (SFI) Grant 13/RC/2073, the SFI CÚRAM Centre 
for Medical Devices. Sarinj Fattah is also supported by COST-UNGAP Action (CA 16205). 
Authors would like to thank Ms. Margot Coady, Mr. Kevin Thornton, and Mr. Marc Farrelly 
(UCD) for technical assistance with tissue histology and animal handling. 
Declaration of interest: David Brayden acts as a consultant to Pharma companies working 
on oral peptide delivery. The other authors have no other relevant affiliations or financial 
involvement with any organization or entity with a financial interest in or financial conflict 
with the subject matter or materials discussed in the manuscript apart from those disclosed. 
No writing assistance was utilized in the production of this manuscript.  
  




Augustijns, P., Wuyts, B., Hens, B., Annaert, P., Butler, J., Brouwers, J., 2014. A review of 
drug solubility in human intestinal fluids: implications for the prediction of oral 
absorption. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 57, 322–332. 
https://doi.org/10.1016/j.ejps.2013.08.027 
Bak, A., Ashford, M., Brayden, D.J., 2018. Local delivery of macromolecules to treat 
diseases associated with the colon. Adv. Drug Deliv. Rev. 136–137, 2–27. 
https://doi.org/10.1016/j.addr.2018.10.009 
Ben-Shlomo, A., Liu, N.-A., Melmed, S., 2017. Somatostatin and dopamine receptor 
regulation of pituitary somatotroph adenomas. Pituitary 20, 93–99. 
https://doi.org/10.1007/s11102-016-0778-2 
Berben, P., Ashworth, L., Beato, S., Bevernage, J., Bruel, J.-L., Butler, J., Dressman, J., 
Schäfer, K., Hutchins, P., Klumpp, L., Mann, J., Nicolai, J., Ojala, K., Patel, S., 
Powell, S., Rosenblatt, K., Tomaszewska, I., Williams, J., Augustijns, P., 2019. 
Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and 
investigation of parameters controlling in vitro precipitation. Eur. J. Pharm. 
Biopharm. 140, 141–148. https://doi.org/10.1016/j.ejpb.2019.04.017 
Berghausen, J., Seiler, F.H., Gobeau, N., Faller, B., 2016. Simulated rat intestinal fluid 
improves oral exposure prediction for poorly soluble compounds over a wide dose 
range. ADMET DMPK 4, 35–53. https://doi.org/10.5599/admet.4.1.258 
Brayden, D.J., Hill, T., Fairlie, D., Maher, S., Mrsny, R., 2020. Systemic Delivery of Peptides 
by the Oral Route: A Combination of Formulation and Medicinal Chemistry. 
Brown, T.D., Whitehead, K.A., Mitragotri, S., 2020. Materials for oral delivery of proteins 
and peptides. Nat. Rev. Mater. 5, 127–148. https://doi.org/10.1038/s41578-019-0156-
6 
         
25 
 
Bucheit, J.D., Pamulapati, L.G., Carter, N., Malloy, K., Dixon, D.L., Sisson, E.M., 2019. Oral 
Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. 
Diabetes Technol. Ther. 22, 10–18. https://doi.org/10.1089/dia.2019.0185 
Buckley, S.T., Bækdal, T.A., Vegge, A., Maarbjerg, S.J., Pyke, C., Ahnfelt-Rønne, J., 
Madsen, K.G., Schéele, S.G., Alanentalo, T., Kirk, R.K., Pedersen, B.L., 
Skyggebjerg, R.B., Benie, A.J., Strauss, H.M., Wahlund, P.-O., Bjerregaard, S., 
Farkas, E., Fekete, C., Søndergaard, F.L., Borregaard, J., Hartoft-Nielsen, M.-L., 
Knudsen, L.B., 2018. Transcellular stomach absorption of a derivatized glucagon-like 
peptide-1 receptor agonist. Sci. Transl. Med. 10. 
https://doi.org/10.1126/scitranslmed.aar7047 
Capatina, C., Wass, J.A.H., 2015. 60 YEARS OF NEUROENDOCRINOLOGY: 
Acromegaly. J. Endocrinol. 226, T141–T160. https://doi.org/10.1530/JOE-15-0109 
Castelli, M.C., Friedman, K., Sherry, J., Brazzillo, K., Genoble, L., Bhargava, P., Riley, 
M.G.I., 2011. Comparing the efficacy and tolerability of a new daily oral vitamin B12 
formulation and intermittent intramuscular vitamin B12 in normalizing low cobalamin 
levels: a randomized, open-label, parallel-group study. Clin. Ther. 33, 358-371.e2. 
https://doi.org/10.1016/j.clinthera.2011.03.003 
Cumming, K.I., Martin, M.L., 2000. Solid oral dosage form containing heparin or a 
heparinoid in combination with a carrier. WO2000048589A1. 
Cuthbert, A.W., Margolius, H.S., 1982. Kinins stimulate net chloride secretion by the rat 
colon. Br. J. Pharmacol. 75, 587–598. https://doi.org/10.1111/j.1476-
5381.1982.tb09178.x 
Drucker, D.J., 2020. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277–
289. https://doi.org/10.1038/s41573-019-0053-0 
         
26 
 
Falavigna, M., Klitgaard, M., Steene, E., Flaten, G.E., 2019. Mimicking regional and 
fasted/fed state conditions in the intestine with the mucus-PVPA in vitro model: The 
impact of pH and simulated intestinal fluids on drug permeability. Eur. J. Pharm. Sci. 
Off. J. Eur. Fed. Pharm. Sci. 132, 44–54. https://doi.org/10.1016/j.ejps.2019.02.035 
Fattah, S., Brayden, D.J., 2017. Progress in the formulation and delivery of somatostatin 
analogs for acromegaly. Ther. Deliv. 8, 867–878. https://doi.org/10.4155/tde-2017-
0064 
Forner, K., Roos, C., Dahlgren, D., Kesisoglou, F., Konerding, M.A., Mazur, J., Lennernäs, 
H., Langguth, P., 2017. Optimization of the Ussing chamber setup with excised rat 
intestinal segments for dissolution/permeation experiments of poorly soluble drugs. 
Drug Dev. Ind. Pharm. 43, 338–346. https://doi.org/10.1080/03639045.2016.1251449 
Fricker, G., Bruns, C., Munzer, J., Briner, U., Albert, R., Kissel, T., Vonderscher, J., 1991. 
Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence 
derivatization. Gastroenterology 100, 1544–1552. 
Fricker, G., Drewe, J., 1995. Enteral absorption of octreotide: modulation of intestinal 
permeability by distinct carbohydrates. J. Pharmacol. Exp. Ther. 274, 826–832. 
Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., Beglinger, C., 1996. Relevance of p-
glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. 
Br. J. Pharmacol. 118, 1841–1847. 
Fricker, G., Drewe, J., Vonderscher, J., Kissel, T., Beglinger, C., 1992. Enteral absorption of 
octreotide. Br. J. Pharmacol. 105, 783–786. 
Gradauer, K., Nishiumi, A., Unrinin, K., Higashino, H., Kataoka, M., Pedersen, B.L., 
Buckley, S.T., Yamashita, S., 2015. Interaction with Mixed Micelles in the Intestine 
Attenuates the Permeation Enhancing Potential of Alkyl-Maltosides. Mol. Pharm. 12, 
2245–2253. https://doi.org/10.1021/mp500776a 
         
27 
 
Hess, S., Rotshild, V., Hoffman, A., 2005. Investigation of the enhancing mechanism of 
sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability 
of polar molecules utilizing a voltage clamp method. Eur. J. Pharm. Sci. Off. J. Eur. 
Fed. Pharm. Sci. 25, 307–312. https://doi.org/10.1016/j.ejps.2005.03.003 
Hopkins, A.M., McDonnell, C., Breslin, N.P., O’Morain, C.A., Baird, A.W., 2002. 
Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with 
an acid secretagogue. J. Pharm. Pharmacol. 54, 341–347. 
https://doi.org/10.1211/0022357021778583 
Ismaiel, O.A., Zhang, T., Jenkins, R., Karnes, H.T., 2011. Determination of octreotide and 
assessment of matrix effects in human plasma using ultra high performance liquid 
chromatography–tandem mass spectrometry. J. Chromatogr. B 879, 2081–2088. 
https://doi.org/10.1016/j.jchromb.2011.05.039 
Jantratid, E., Janssen, N., Reppas, C., Dressman, J.B., 2008. Dissolution media simulating 
conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25, 
1663–1676. https://doi.org/10.1007/s11095-008-9569-4 
Jones, C.R., Hatley, O.J.D., Ungell, A.-L., Hilgendorf, C., Peters, S.A., Rostami-Hodjegan, 
A., 2016. Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction 
of Human Drug Absorption and First-Pass Elimination. AAPS J. 18, 589–604. 
https://doi.org/10.1208/s12248-016-9889-y 
Kisser, B., Mangelsen, E., Wingolf, C., Partecke, L.I., Heidecke, C.-D., Tannergren, C., 
Oswald, S., Keiser, M., 2017. The Ussing Chamber Assay to Study Drug Metabolism 
and Transport in the Human Intestine. Curr. Protoc. Pharmacol. 77, 7.17.1-7.17.19. 
https://doi.org/10.1002/cpph.22 
Kristin, F., René, H., Boontida, M., Buraphacheep, J.V., Maximilian, A., Johanna, M., Peter, 
L., 2017. Dissolution and dissolution/permeation experiments for predicting systemic 
         
28 
 
exposure following oral administration of the BCS class II drug clarithromycin. Eur. 
J. Pharm. Sci. 101, 211–219. https://doi.org/10.1016/j.ejps.2017.02.003 
Lau, J.L., Dunn, M.K., 2018. Therapeutic peptides: Historical perspectives, current 
development trends, and future directions. Bioorg. Med. Chem. 26, 2700–2707. 
https://doi.org/10.1016/j.bmc.2017.06.052 
Lennernäs, H., 2007. Intestinal permeability and its relevance for absorption and elimination. 
Xenobiotica 37, 1015–1051. https://doi.org/10.1080/00498250701704819 
Leone-Bay, A., Leipold, H., Sarubbi, D., Variano, B., Rivera, T., Baughman, R.A., 1996. 
Oral delivery of sodium cromolyn: preliminary studies in vivo and in vitro. Pharm. 
Res. 13, 222–226. https://doi.org/10.1023/a:1016034913181 
Leone-Bay, A., Paton, D.R., Variano, B., Leipold, H., Rivera, T., Miura-Fraboni, J., 
Baughman, R.A., Santiago, N., 1998. Acylated non-alpha-amino acids as novel agents 
for the oral delivery of heparin sodium, USP. J. Control. Release Off. J. Control. 
Release Soc. 50, 41–49. https://doi.org/10.1016/s0168-3659(97)00101-6 
Lim, D.S.T., Fleseriu, M., 2017. The role of combination medical therapy in the treatment of 
acromegaly. Pituitary 20, 136–148. https://doi.org/10.1007/s11102-016-0737-y 
Maher, S., Brayden, D.J., Casettari, L., Illum, L., 2019. Application of Permeation Enhancers 
in Oral Delivery of Macromolecules: An Update. Pharmaceutics 11. 
https://doi.org/10.3390/pharmaceutics11010041 
Maher, S., Heade, J., McCartney, F., Waters, S., Bleiel, S.B., Brayden, D.J., 2018. Effects of 
surfactant-based permeation enhancers on mannitol permeability, histology, and 
electrogenic ion transport responses in excised rat colonic mucosae. Int. J. Pharm. 
539, 11–22. https://doi.org/10.1016/j.ijpharm.2018.01.008 
Maher, S., Kennelly, R., Bzik, V.A., Baird, A.W., Wang, X., Winter, D., Brayden, D.J., 2009. 
Evaluation of intestinal absorption enhancement and local mucosal toxicity of two 
         
29 
 
promoters. I. Studies in isolated rat and human colonic mucosae. Eur. J. Pharm. Sci. 
38, 291–300. https://doi.org/10.1016/j.ejps.2009.09.001 
Maher, S., Mrsny, R.J., Brayden, D.J., 2016. Intestinal permeation enhancers for oral peptide 
delivery. Adv. Drug Deliv. Rev., Oral delivery of peptides 106, 277–319. 
https://doi.org/10.1016/j.addr.2016.06.005 
Maroni, A., Zema, L., Del Curto, M.D., Foppoli, A., Gazzaniga, A., 2012. Oral colon 
delivery of insulin with the aid of functional adjuvants. Adv. Drug Deliv. Rev. 64, 
540–556. https://doi.org/10.1016/j.addr.2011.10.006 
McCartney, F., Jannin, V., Chevrier, S., Boulghobra, H., Hristov, D.R., Ritter, N., Miolane, 
C., Chavant, Y., Demarne, F., Brayden, D.J., 2019. Labrasol® is an efficacious 
intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies. J. 
Control. Release Off. J. Control. Release Soc. 310, 115–126. 
https://doi.org/10.1016/j.jconrel.2019.08.008 
Melmed, S., Popovic, V., Bidlingmaier, M., Mercado, M., van der Lely, A.J., Biermasz, N., 
Bolanowski, M., Coculescu, M., Schopohl, J., Racz, K., Glaser, B., Goth, M., 
Greenman, Y., Trainer, P., Mezosi, E., Shimon, I., Giustina, A., Korbonits, M., 
Bronstein, M.D., Kleinberg, D., Teichman, S., Gliko-Kabir, I., Mamluk, R., Haviv, 
A., Strasburger, C., 2015. Safety and efficacy of oral octreotide in acromegaly: results 
of a multicenter phase III trial. J. Clin. Endocrinol. Metab. 100, 1699–1708. 
https://doi.org/10.1210/jc.2014-4113 
MYCAPSSA [WWW Document], 2020. URL 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208232s000lbl.pdf 
Naylor, M.R., Bockus, A.T., Blanco, M.-J., Lokey, R.S., 2017. Cyclic peptide natural 
products chart the frontier of oral bioavailability in the pursuit of undruggable targets. 
Curr. Opin. Chem. Biol. 38, 141–147. https://doi.org/10.1016/j.cbpa.2017.04.012 
         
30 
 
Novel Approaches for Enhancing the Oral Bioavailability & Absorption of Peptides [WWW 
Document], 2020. URL https://curtiscoulter.com/enhancing-oral-bioavailability-
absorption-of-peptides/ (accessed 5.15.20). 
Park, Kyeongsoon, Kwon, I.C., Park, Kinam, 2011. Oral protein delivery: Current status and 
future prospect. React. Funct. Polym., Special Issue in Celebration of the 60th 
Birthday of Professor Kazunori Kataoka 71, 280–287. 
https://doi.org/10.1016/j.reactfunctpolym.2010.10.002 
Petersen, S.B., Nolan, G., Maher, S., Rahbek, U.L., Guldbrandt, M., Brayden, D.J., 2012. 
Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison 
between rat intestinal mucosal sheets and Caco-2 monolayers. Eur. J. Pharm. Sci. Off. 
J. Eur. Fed. Pharm. Sci. 47, 701–712. https://doi.org/10.1016/j.ejps.2012.08.010 
Pless, J., 2005. The history of somatostatin analogs. J. Endocrinol. Invest. 28, 1–4. 
Rybelsus® (oral semaglutide), 2020. . GlobeNewswire. 
RYBELSUS® [WWW Document], 2020. URL https://www.rybelsuspro.com/ (accessed 
5.25.20). 
Smith, L., Mosley, J., Ford, M., Courtney, J., 2016. Cyanocobalamin/Salcaprozate Sodium: A 
Novel Way to Treat Vitamin B12 Deficiency and Anemia. J. Hematol. Oncol. Pharm. 
6, 42–45. 
Strasburger, C.J., Karavitaki, N., Störmann, S., Trainer, P.J., Kreitschmann-Andermahr, I., 
Droste, M., Korbonits, M., Feldmann, B., Zopf, K., Sanderson, V.F., Schwicker, D., 
Gelbaum, D., Haviv, A., Bidlingmaier, M., Biermasz, N.R., 2016. Patient-reported 
outcomes of parenteral somatostatin analogue injections in 195 patients with 
acromegaly. Eur. J. Endocrinol. 174, 355–362. https://doi.org/10.1530/EJE-15-1042 
         
31 
 
Stuettgen, V., Brayden, D.J., 2020. Investigations of Piperazine Derivatives as Intestinal 
Permeation Enhancers in Isolated Rat Intestinal Tissue Mucosae. AAPS J. 22, 33. 
https://doi.org/10.1208/s12248-020-0416-9 
Tuvia, S., Pelled, D., Marom, K., Salama, P., Levin-Arama, M., Karmeli, I., Idelson, G.H., 
Landau, I., Mamluk, R., 2014. A novel suspension formulation enhances intestinal 
absorption of macromolecules via transient and reversible transport mechanisms. 
Pharm. Res. 31, 2010–2021. https://doi.org/10.1007/s11095-014-1303-9 
Twarog, C., 2020. Comparison of the intestinal permeation enhancers, SNAC and C10, for 
oral peptides: biophysical, in vitro and ex vivo studies. Université Paris-Saclay and 
University College Dublin. 
Twarog, C., Fattah, S., Heade, J., Maher, S., Fattal, E., Brayden, D.J., 2019. Intestinal 
Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between 
Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics 11. 
https://doi.org/10.3390/pharmaceutics11020078 
Ungell, A.L., Nylander, S., Bergstrand, S., Sjöberg, A., Lennernäs, H., 1998. Membrane 
transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 
87, 360–366. https://doi.org/10.1021/js970218s 
van der Merwe, S.M., Verhoef, J.C., Verheijden, J.H.M., Kotzé, A.F., Junginger, H.E., 2004. 
Trimethylated chitosan as polymeric absorption enhancer for improved peroral 
delivery of peptide drugs. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft 
Pharm. Verfahrenstechnik EV 58, 225–235. 
https://doi.org/10.1016/j.ejpb.2004.03.023 
Vertzoni, M., Augustijns, P., Grimm, M., Koziolek, M., Lemmens, G., Parrott, N., 
Pentafragka, C., Reppas, C., Rubbens, J., Van Den Αbeele, J., Vanuytsel, T., 
Weitschies, W., Wilson, C.G., 2019. Impact of regional differences along the 
         
32 
 
gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. 
Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 134, 153–175. 
https://doi.org/10.1016/j.ejps.2019.04.013 
Vertzoni, M., Diakidou, A., Chatzilias, M., Söderlind, E., Abrahamsson, B., Dressman, J.B., 
Reppas, C., 2010. Biorelevant media to simulate fluids in the ascending colon of 
humans and their usefulness in predicting intracolonic drug solubility. Pharm. Res. 
27, 2187–2196. https://doi.org/10.1007/s11095-010-0223-6 
Wang, J., Yadav, V., Smart, A.L., Tajiri, S., Basit, A.W., 2015. Toward oral delivery of 
biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. 
Mol. Pharm. 12, 966–973. https://doi.org/10.1021/mp500809f 
Wuyts, B., Riethorst, D., Brouwers, J., Tack, J., Annaert, P., Augustijns, P., 2015. Evaluation 
of fasted and fed state simulated and human intestinal fluids as solvent system in the 
Ussing chambers model to explore food effects on intestinal permeability. Int. J. 
Pharm. 478, 736–744. https://doi.org/10.1016/j.ijpharm.2014.12.021 
Yamamoto, A., Okagawa, T., Kotani, A., Uchiyama, T., Shimura, T., Tabata, S., Kondo, S., 
Muranishi, S., 1997. Effects of different absorption enhancers on the permeation of 
ebiratide, an ACTH analogue, across intestinal membranes. J. Pharm. Pharmacol. 49, 
1057–1061. https://doi.org/10.1111/j.2042-7158.1997.tb06041.x 
Yang, L.P.H., Keating, G.M., 2010. Octreotide long-acting release (LAR): a review of its use 




         
33 
 
Table 1. Buffer compositions on the apical side of rat and human intestinal mucosae in 
Ussing chambers 
KH rSIF FaSSIF-V2 FaSSCoF * 
118 mM NaCl 18.7 mM NaCl 68.6 mM NaCl 
0.15 mM sodium 
cholate  
4.7 mM KCl 
5 mM sodium 
taurocholate 
3 mM sodium 
taurocholate 
0.3 mM Lecithin 
2.5 mM CaCl2 
12.5 mM sodium 
cholate hydrate 
0.2 mM Lecithin 0.1 mM sodium oleate 
1.2 mM MgSO4 
7.5 mM sodium 
chenodeoxycholic acid 
19.1 mM malenic 45.4 mM Tris 
1.2 mM KH2PO4 5.2 mM Lecithin 
34.8 mM sodium 
hydroxide 
120 mM sodium 
hydroxide 
25 mM NaHCO3 0.3 mM sodium oleate   
11.1 mM glucose 
1.7 mM glyceryl 
monooleate 
  
 29.9 mM malenic   
* human colonic mucosae studies only. In all studies KH was used on the basolateral side. 
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Figure legends:  
Figure 1. Representative images of dissected human colonic mucosae for Ussing system. (A) 
Human colonic specimen, (B) Colonic tissue after removing smooth muscle; the luminal side 
is faced down on the dissection board, (C) Muscle-stripped mucosae mounted tissue on an 
Ussing chamber. Horizontal bars = 35 mm. 
 
Figure 2. Papp of [
3
H]-octreotide and TEER across rat intestinal regional mucosae. A. Papp of 
[
3
H]-octreotide in absence and presence of 20 mM SNAC in KH buffer, 
* 
P < 0.05, (Student’s 
unpaired t-test) comparing Papp in the presence of SNAC against regional controls exposed to 
[
3
H]-octreotide alone. B-F. Percentile of initial TEER in tissues exposed either to [
3
H]-
octreotide alone or to SNAC and [
3
H]-octreotide. B. Stomach, C. Duodenum D. Jejunum, E. 
Ileum, F. Colon. 
* 
P < 0.05, two-way ANOVA followed by Bonferroni post hoc analysis 
comparing TEER values within regions. Data expressed as Mean ± SEM (n= 6-7 per group). 
The dotted line indicates when a significant TEER reduction was seen at particular time point 
compared to the corresponding control of [
3
H]-octreotide alone. 




Figure 3. A. Papp of [
3
H]-octreotide in the absence and presence of 20 mM SNAC in KH, 
rSIF, and FaSSIF-V2 in rat jejunal mucosae. 
*
P < 0.05, one-way ANOVA followed by 
Dunnett’s post hoc analysis comparing the Papp in rSIF and FaSSIF-V2 in the presence of 20 
mM SNAC to that seen in KH buffer. B. Percentile of initial TEER in the controls and in the 
presence of 20 mM SNAC in different buffers, 
*
P < 0.05, two-way ANOVA followed by 
Bonferroni post hoc analysis to compare reduction in TEER in tissue exposed to SNAC 
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versus the control from individual regions. Data represent Mean ± SEM (n= 3-7). The dotted 
line indicates when a significant TEER reduction was seen at particular time point compared 
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Figure 4. Papp of [
3
H]-octreotide and unlabelled octreotide across human colonic mucosae in 
the presence of SNAC in KH buffer. A. Papp of [
3
H]-octreotide, B. percentile of initial TEER 
(with [
3
H]-octreotide alone used in controls), C. Papp of unlabelled octreotide, D. percentile of 
initial TEER (with unlabelled octreotide alone used in controls). Mean ± SEM (n= 3-6 per 
group). 
*
P < 0.05, A: one-way ANOVA followed by Dunnett’s post hoc analysis, C: 
Student’s unpaired t-test, and B and D: two-way ANOVA followed by Bonferroni post hoc 
analysis to compare reduction in TEER in presence of SNAC to the control. The dotted line 
indicates when a significant TEER reduction was seen at particular time point compared to 




Figure 5. Papp of [
3
H]-octreotide in the absence and presence of SNAC using FaSSCoF on the 
apical side of human colonic mucosae. A. Papp of [
3
H]-octreotide and B. percentile of initial 
TEER in FaSSCoF. Data is Mean ± SEM (n= 3). 
*
P < 0.05, A: one-way ANOVA followed 
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by Dunnett’s post hoc analysis, and B: two-way ANOVA followed by Bonferroni post hoc 
analysis to compare reduction in TEER in presence of SNAC to the controls exposed to [
3
H]-
octreotide alone. The dotted line indicates when a significant TEER reduction was seen at 
particular time point compared to the corresponding control [
3
H]-octreotide alone. 




Figure 6. Representative images of A. rat regional mucosae and B. human colonic stained 
with H&E following exposure to SNAC in KH buffer for 120 min. Horizontal bars = 150-250 
μm. (i) intact villi, (ii) erosion at tip of villi, (iii) erosion of villi and (iv) odema. 
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